Filters

Ghassan K Abou-Alfa, Stephan L Chan, Chia-Chi Lin, E Gabriela Chiorean, Randall F Holcombe, Mary F Mulcahy, William D Carter, Kashyap Patel, William R Wilson, Teresa J Melink, John C Gutheil, Chao-Jung Tsao

Cancer chemotherapy and pharmacology 2011;68(2):539-45

Full Text

Abstract

Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study.

J A Cancelas, L Corash, S Rico, A Erickson, N Mufti, N Huang, A North, M A Schott, S Graminske, N Rugg, J L Gottschall

Vox sanguinis 2017;112(3):210-218

Full Text

Abstract

Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.

Viviane Ponath, Alexander Bürkle, Annette Schmidt, Dirk Steinritz, Horst Thiermann, Markus Siegert, Romano Strobelt, Waltraud Burckhardt-Boer, Rita Martello, Kirsten Lex, Frank Balszuweit, Matthias Birtel, Malgorzata Debiak, Aswin Mangerich

Toxicology letters 2016;244():56-71

Full Text

Abstract

Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.

Paris S Mitrou, Mathias J Rummel, Dieter Hoelzer

Seminars in oncology 2002;29(4 Suppl 13):27-32

Full Text

Abstract

Results: 1 – 15 / 16

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Nitrogen Mustard Compounds""[mesh_terms]

Nitrogen Mustards as Anticancer Chemotherapies: Historic Perspective, Current Developments and Future Trends.

DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A.

Biochemistry of N-mustard tumour control compounds reconsidered.

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.

Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War.

Potentiation by caffeine of cytogenetic damage induced by steroidal derivatives in human lymphocytes in vitro.

Update of pathogen reduction technology for therapeutic plasma.

Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.

The cytotoxicity of benzaldehyde nitrogen mustard-2-pyridine carboxylic acid hydrazone being involved in topoisomerase IIα inhibition.

Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.

Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study.

Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.

Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.

Results for
""Nitrogen Mustard Compounds""[mesh_terms]